Sirona Biochem Unveils Breakthrough Research Findings
VANCOUVER, British Columbia — Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) has recently celebrated a significant milestone in the field of skincare with the publication of pivotal research in the widely respected Journal of Cosmetic Dermatology.
About the Pioneering Study
The published article, titled “TFC-1326 Compound Reduces Clinical Signs of Skin Aging: Evidence From In Vitro Human Adipose and Skin Models and Pilot Clinical Trial,” explores the groundbreaking effectiveness of Sirona’s proprietary compound, TFC-1326, especially in minimizing visible signs of aging in the skin.
Study Overview and Key Outcomes
This study was executed by top-tier scientists at Diva Expertise in collaboration with Sirona Biochem. The team provided robust data showcasing how TFC-1326 interacts with essential processes tied to skin aging.
Utilizing advanced human adipose and skin models, along with results from a pilot clinical trial, the research revealed that TFC-1326 could:
- Boost skin elasticity and overall firmness
- Encourage the production of collagen, vital for skin structure
- Significantly reduce fine lines and wrinkles
Insights from Clinical Trials
The pilot trial involving a 1% TFC-1326 topical cream yielded convincing evidence supporting its safety and efficacy. Certain outcomes highlighted in the study included:
- Apparent enhancement in skin texture, hydration, and overall appearance
These notable results reinforce the compound's potential to shape the future of anti-aging solutions in the cosmetic industry.
Leadership Praise and Future Plans
Dr. Howard Verrico, CEO of Sirona Biochem, shared, “Our innovative approach to carbohydrate chemistry has once again delivered transformative results. The publication of these findings in the Journal of Cosmetic Dermatology underscores the significant cosmeceutical advantages of TFC-1326 for aging skin. We believe this compound is set to revolutionize anti-aging skincare solutions.”
Additionally, Dr. Verrico noted, “This represents a key milestone for our company. We are diligently moving forward with discussions involving potential commercial partnerships while also preparing to introduce our own products, making sure this groundbreaking technology reaches consumers across the globe.”
Trademark and Product Information
TFC-1326 and its corresponding salt form, TFC-1325, are marketed under the trademarked name GlycoProteMim.
Spotlight on Diva Expertise
Diva Expertise, located in the Biotechnologies Center of Pierre Potier in France, is known for its outstanding research on human adipose tissue. With over 15 years of specialization in physiology and physiopathology, Diva Expertise has achieved recognition as a leader in the field.
The organization employs cutting-edge technology offering personalized research support across various studies, from cellular-level explorations to applications for human benefit. Adipose tissue, constituting the hypodermis, plays a crucial role in skin maintenance, presenting a pivotal target for innovative anti-aging strategies.
About Sirona Biochem Corp.
As a dedicated biotechnology firm, Sirona Biochem focuses on developing innovative cosmetic and dermatological active ingredients through its proprietary platform technology. The company specializes in enhancing carbohydrate molecules for improved efficacy and safety, and its licensed compounds generate revenue globally through various means such as licensing fees, milestone payments, and royalties.
Sirona’s laboratory, TFChem, is based in France and recognized for its contributions in the scientific community, having received multiple awards and grants from the French government and the European Union.
Contact Information
Investor Enquiries:
Christopher Hopton
Chief Financial Officer
(604) 641-4466
info@sironabiochem.com
Frequently Asked Questions
What is the focus of Sirona Biochem's recent study?
The study focuses on the effectiveness of TFC-1326, a compound developed by Sirona Biochem, in reducing signs of skin aging.
How does TFC-1326 work to improve skin health?
TFC-1326 enhances skin elasticity, stimulates collagen production, and reduces fine lines and wrinkles.
Who conducted the study on TFC-1326?
The study was carried out by scientists at Diva Expertise in collaboration with Sirona Biochem Corp.
What are the future plans for TFC-1326?
Sirona Biochem is in discussions with potential commercial partners and preparing to launch their own products featuring TFC-1326.
What is the significance of the publication in the Journal of Cosmetic Dermatology?
The publication affirms TFC-1326's cosmeceutical benefits, enhancing its credibility and market potential in anti-aging solutions.
